VERAXA Biotech (NASDAQ: VRXA), a Switzerland-based biotechnology company with a key financial and regulatory presence in the U.S., is expanding its use of human-relevant testing methods across its oncology research programs. The strategy aims to generate more clinically informative preclinical data while reducing the number of animals required for drug development, according to an October 7, 2026, company announcement.
The company is implementing New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling, and three-dimensional spheroid models. These methods are aligned with FDA guidance and are being applied across VERAXA’s preclinical research programs. The company says the approach is designed to improve the relevance of experimental findings to human biology while reducing animal testing.
The NAMs strategy supports the development of VERAXA’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. This is particularly important for bispecific antibodies, which must simultaneously bind two different targets to function correctly.
In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This suggests the candidate’s activity is target-specific rather than a generalized effect.
The implications of this announcement extend beyond animal welfare. By using human-relevant models earlier in the drug development process, VERAXA aims to reduce the risk of late-stage clinical failures that arise when animal data do not translate to humans. For investors, the strategy could potentially shorten development timelines and lower costs, though the company notes that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially. As a clinical-stage biotechnology company, VERAXA’s success depends on the eventual approval of its drug candidates, and the NAMs approach is intended to strengthen the scientific foundation of its pipeline.
VERAXA is an emerging leader in designing novel cancer therapies, and its focus on human-relevant testing reflects a broader industry trend toward methods that better predict human responses. The company’s BiTAC platform is central to its pipeline, and the expanded use of NAMs is expected to support multiple programs. For readers following the biotechnology sector, VERAXA’s progress with these methodologies may offer a signal about how preclinical data quality is evolving. The company’s newsroom, available through https://ibn.fm/VRXA, provides the latest updates relating to VRXA. Additional details about the announcement are available via the Read More link, and the original release can be viewed on www.newmediawire.com. Terms of use and disclaimers applicable to all content provided by IBN are available at https://IBN.ai/Disclaimer.
